Peripheral Neuropathy News and Research RSS Feed - Peripheral Neuropathy News and Research

Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Targeted drug doubles progression free survival in Hodgkin lymphoma

Targeted drug doubles progression free survival in Hodgkin lymphoma

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months). [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

New animal studies at Henry Ford Hospital found that sildenafil, a drug commonly used to treat erectile dysfunction, may be effective in relieving painful and potentially life-threatening nerve damage in men with long-term diabetes. [More]
TCC-EZ Casting System dramatically increases healing process of diabetic foot ulcers

TCC-EZ Casting System dramatically increases healing process of diabetic foot ulcers

Diabetics once facing the prospect of amputation to their lower limbs due to the effects of foot ulcers are now back on their feet thanks to a new technology. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
Henry Ford researchers propose new treatment strategy for stroke, other neurological disorders

Henry Ford researchers propose new treatment strategy for stroke, other neurological disorders

Medicine should reconsider how it treats stroke and other neurological disorders, focusing on the intrinsic abilities of the brain and nervous system to heal themselves rather than the "modest" benefits of clot-busting drugs and other neuroprotective treatments. [More]
Novel technology could improve diagnosis of peripheral arterial disease

Novel technology could improve diagnosis of peripheral arterial disease

Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque buildup. The plaque accumulation leads to an insufficient blood flow to the body's extremities and increases a person's risk for heart attack and stroke by up to six times. PAD is also one of the most serious complications of diabetes. [More]
Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA. [More]
Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. [More]
Advances in stem cell therapy can improve outcomes for patients with chronic diabetic foot ulcers

Advances in stem cell therapy can improve outcomes for patients with chronic diabetic foot ulcers

According to data presented at the 73rd Annual Scientific Conference of the American College of Foot and Ankle Surgeons, advances in stem cell therapy can significantly improve outcomes for patients with chronic diabetic foot ulcers. Use of stem cells to treat foot problems like diabetic ulcers may speed up the healing process, preventing infection and hospitalization during recovery. [More]
Research findings may point to new treatment for patients with Mitofusin 2 deficiency

Research findings may point to new treatment for patients with Mitofusin 2 deficiency

Researchers have discovered a novel role for Mitofusin 2, and the findings may point to a new treatment for patients with diseases caused by loss of the mitochondrial protein. [More]
Scientists identify first genetic marker linked to severe neurological toxicity

Scientists identify first genetic marker linked to severe neurological toxicity

Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours. However, its use frequently causes peripheral neuropathies, neurological problems that affect the vast majority of patients. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
Drug combination shows promise in patients with newly diagnosed multiple myeloma

Drug combination shows promise in patients with newly diagnosed multiple myeloma

The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology. [More]
Dr. Grace Campbell receives RNF Fellow Research Grant Award

Dr. Grace Campbell receives RNF Fellow Research Grant Award

The Rehabilitation Nursing Foundation (RNF) presents Dr. Grace Campbell, PhD BSN RN CRRN MSW, with the RNF Fellow Research Grant Award. RNF offers $30,000 in the form of multiple grants for research projects that address the clinical practice, educational or administrative dimensions of rehabilitation nursing. Dr. Campbell received her award at the ARN 40th Annual Educational Conference, October 29 - November 1, 2014 in Anaheim, CA. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Regular participation in physical activity may help reduce weight and treat diabetes

Regular participation in physical activity may help reduce weight and treat diabetes

A study of exercise habits in people with diabetes finds that women with diabetes who are trying to lose weight are far more physically active than women with diabetes who are not trying to control their weight. [More]
Loss of sensation in the feet of diabetics may predict heart attack, stroke

Loss of sensation in the feet of diabetics may predict heart attack, stroke

Experts have discovered that loss of sensation in the feet, a result of diabetes, may be a predictor of cardiovascular events such as heart attack and strokes. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). [More]
Advertisement
Advertisement